Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Metastatic Pancreatic Cancer
Interventions: nab-paclitaxel, gemcitabine, placebo, Necuparanib; Drug
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 27 more

Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Interventions: ION440, Sham procedure; Drug · Procedure
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: San Diego, California • Aurora, Colorado • Baltimore, Maryland + 5 more

Conditions: Pain
Interventions: VX-708, Itraconazole, Midazolam, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Parenteral Nutrition
Interventions: Sodium Glycerophosphate Injection, Sodium Phosphates Injection; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: High Blood Pressure, Liver Transplant, Renal Function Abnormal
Interventions: Amlodipine Besylate, Chlorthalidone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: AZD4831; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy
Interventions: Maraviroc, Fosamprenavir, Ritonavir; Drug
Lead sponsor: Garden State Infectious Disease Associates, PA; Other
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: Arthroplasty, Replacement, Knee
Interventions: Comprehensive Behavioral Intervention, Standard of Care Exercise Program; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alcohol Use Disorder
Interventions: Peer recovery coaching (PRC), Brief Intervention (SBIRT); Behavioral
Lead sponsor: Clemson University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Greenville, South Carolina • Seneca, South Carolina

Conditions: Trigeminal Neuralgia
Interventions: Basimglurant, Placebo; Drug · Other
Lead sponsor: Noema Pharma AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: La Jolla, California • Miami, Florida • Tampa, Florida + 5 more

Conditions: Tourniquet Placement, Wound Packing
Interventions: Simulation; Other
Lead sponsor: White Plains Hospital; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Timeline: 2019
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Interventions: Minnelide™Capsules; Drug
Lead sponsor: Minneamrita Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more

Conditions: Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Pulsed Electromagnetic Field (PEMF) Therapy; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Pain
Interventions: LightForce EXPi; Device
Lead sponsor: LiteCure LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Crohn's Disease
Interventions: Placebo, TD-1473; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 44
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 39 more

Conditions: Smoking, Tobacco Use
Interventions: Product A, Product B, Product C, Product D, Product E, Product F, Product G, Product N; Other
Lead sponsor: RAI Services Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Lexington, Kentucky • Knoxville, Tennessee

Conditions: Healthy Volunteers
Interventions: NUV001 active cohort 1, NUV001 active cohort 2, NUV001 active cohort 3, NUV001 active cohort 4, NUV001 placebo cohort 1, NUV001 placebo cohort 2, NUV001 placebo cohort 3, NUV001 placebo cohort 4; Drug
Lead sponsor: Nuvamid SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Malignant Neoplasm
Interventions: quality-of-life assessment, telephone-based intervention, questionnaire administration, counseling intervention, exercise intervention, educational intervention, standard follow-up care; Procedure · Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neuropsychiatric Syndromes
Interventions: PET with radiotracer [11C]PBR-28 ( or [11C]ER176), Affective challenge; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 4 more

Conditions: Fatigue
Interventions: Creatine Monohydrate, Control; Dietary Supplement
Lead sponsor: Ward Dobbs; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: La Crosse, Wisconsin

Conditions: Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
Interventions: Cyanocobalamin, Dulaglutide; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

The Feasibility of a Comprehensive Behavioral Intervention in Patient Post TKA

A Peer Recovery Coaching Intervention for Hospitalized Alcohol Use Disorder Patients

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

Effectiveness of the Adding High Fidelity Simulation to the Bleeding Control Course in Regards to Proper Tourniquet Placement Amongst School Personnel

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome

Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning

Efficacy and Safety of TD-1473 in Crohn's Disease

Modern Nicotine Oral Product Abuse Liability

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Structured Multidisciplinary Intervention or Standard Medical Care in Improving Quality of Life in Patients Receiving Active Cancer Treatment

Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: a Dimensional Approach

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

The Effects of Nutritional Supplementation on Occupational Performance in Firefighters

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response